1. Home
  2. AGIO vs SXI Comparison

AGIO vs SXI Comparison

Compare AGIO & SXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • SXI
  • Stock Information
  • Founded
  • AGIO 2007
  • SXI 1955
  • Country
  • AGIO United States
  • SXI United States
  • Employees
  • AGIO N/A
  • SXI N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • SXI Industrial Machinery/Components
  • Sector
  • AGIO Health Care
  • SXI Industrials
  • Exchange
  • AGIO Nasdaq
  • SXI Nasdaq
  • Market Cap
  • AGIO 2.4B
  • SXI 2.6B
  • IPO Year
  • AGIO 2013
  • SXI N/A
  • Fundamental
  • Price
  • AGIO $40.72
  • SXI $213.24
  • Analyst Decision
  • AGIO Strong Buy
  • SXI Strong Buy
  • Analyst Count
  • AGIO 5
  • SXI 4
  • Target Price
  • AGIO $57.25
  • SXI $223.50
  • AVG Volume (30 Days)
  • AGIO 577.5K
  • SXI 96.2K
  • Earning Date
  • AGIO 10-30-2025
  • SXI 10-28-2025
  • Dividend Yield
  • AGIO N/A
  • SXI 0.60%
  • EPS Growth
  • AGIO N/A
  • SXI N/A
  • EPS
  • AGIO 11.13
  • SXI 4.64
  • Revenue
  • AGIO $40,875,000.00
  • SXI $790,107,000.00
  • Revenue This Year
  • AGIO $23.76
  • SXI $14.61
  • Revenue Next Year
  • AGIO $148.23
  • SXI $7.59
  • P/E Ratio
  • AGIO $3.67
  • SXI $45.99
  • Revenue Growth
  • AGIO 30.57
  • SXI 9.64
  • 52 Week Low
  • AGIO $23.42
  • SXI $128.85
  • 52 Week High
  • AGIO $62.58
  • SXI $218.62
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 63.66
  • SXI 57.31
  • Support Level
  • AGIO $39.32
  • SXI $199.80
  • Resistance Level
  • AGIO $41.42
  • SXI $218.62
  • Average True Range (ATR)
  • AGIO 1.34
  • SXI 5.72
  • MACD
  • AGIO 0.34
  • SXI 0.28
  • Stochastic Oscillator
  • AGIO 87.58
  • SXI 69.23

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

Share on Social Networks: